Sorrento Therapeutics Inc Stock Other OTC
Equities
US83587F1030
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Apr. 10 | Sorrento Therapeutics, Inc. Emerged from Bankruptcy | CI |
Mar. 15 | Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs | MT |
Financials (USD)
Sales 2021 | 52.9M | Sales 2022 | 62.84M | Capitalization | 411M |
---|---|---|---|---|---|
Net income 2021 | -428M | Net income 2022 | -573M | EV / Sales 2021 | 29.1 x |
Net Debt 2021 | 111M | Net Debt 2022 | 84.53M | EV / Sales 2022 | 7.89 x |
P/E ratio 2021 |
-3.2
x | P/E ratio 2022 |
-0.65
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 97.77% |
Managers | Title | Age | Since |
---|---|---|---|
Henry Ji
CEO | Chief Executive Officer | 59 | 88-12-31 |
Shawn Sahebi
COO | Chief Operating Officer | - | - |
Mike A. Royal
CTO | Chief Tech/Sci/R&D Officer | 70 | 14-03-02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kim D. Janda
BRD | Director/Board Member | 67 | 12-03-31 |
David Lemus
BRD | Director/Board Member | 61 | 17-09-30 |
Jaisim Shah
BRD | Director/Board Member | 63 | 13-09-10 |
1st Jan change | Capi. | |
---|---|---|
+16.73% | 121B | |
+13.04% | 107B | |
-5.80% | 24.82B | |
+1.69% | 22.48B | |
-10.09% | 18.32B | |
-40.52% | 16.33B | |
-14.00% | 15.31B | |
+1.18% | 14.08B | |
+24.18% | 11.74B |